Basilea Pharmaceutica International
Ltd, Allschwil
Dba Basilea Pharmaceutica
International Ltd, Allschwil
CAGE Code: SSU10
NCAGE Code: SSU10
Status: Active
Type: Commercial Supplier
Summary
Basilea Pharmaceutica International, Ltd, Allschwil, Dba Basilea Pharmaceutica, International Ltd, Allschwil is an Active Commercial Supplier with the Cage Code SSU10.
Address
Hegenheimermattweg 167B
Allschwil
Basel Land
4123
Switzerland
Points of Contact
Related Information
No Related Information...
People who viewed this 'CAGE Code' also viewed...
North Power Construction Company Newyork Eagle Construction Company Super Jet Group Sina Aria Logistic And Trading Arif Noor Construction Company,Ltd Melad Abrar Intl. Transit And Bashir Qayum Logistics Services Dostamani Construction Company Sayed Zawar Ali Khan Renewable Energy Agency Jlcc Mohammad Eisa Sardarzada Well Naweed Insaaf Construction Company Aria Roshan Trading Company Inc Abdul Waris Kamran Road And Priority Development Stratigic Co Ace Limited Liability Company Asct Group Seroosh Services Lux Star Construction Company
Frequently Asked Questions (FAQ) for CAGE SSU10
- What is CAGE Code SSU10?
- SSU10 is the unique identifier used by NATO Organizations to reference the physical entity known as Basilea Pharmaceutica International Ltd, Allschwil Dba Basilea Pharmaceutica International Ltd, Allschwil located at Hegenheimermattweg 167B, Allschwil, Basel Land, 4123, Switzerland.
- Who is CAGE Code SSU10?
- SSU10 refers to Basilea Pharmaceutica International Ltd, Allschwil Dba Basilea Pharmaceutica International Ltd, Allschwil located at Hegenheimermattweg 167B, Allschwil, Basel Land, 4123, Switzerland.
- Where is CAGE Code SSU10 Located?
- CAGE Code SSU10 is located in Allschwil, Switzerland.
Contracting History for CAGE SSU10 Most Recent 25 Records
- HHSO100201600002C
- Advanced Development Of Ceftobiprole
- 9 Jun 2022
- Advanced Development Of Ceftobiprole
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $108,736,742.00
- Department Of Health And Human Services (Hhs)
- HHSO100201600002C
- Igf::Ot::Igf Advanced Development Of Ceftobiprole
- 22 May 2019
- Igf::Ot::Igf Advanced Development Of Ceftobiprole
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $108,736,742.00
- Department Of Health And Human Services (Hhs)
- HHSO100201600002C
- Advanced Development Of Ceftobiprole
- 4 Sep 2019
- Advanced Development Of Ceftobiprole
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $94,908,924.00
- Department Of Health And Human Services (Hhs)
- HHSO100201600002C
- Advanced Development Of Ceftobiprole
- 27 May 2020
- Advanced Development Of Ceftobiprole
- Office Of Acq&Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $102,908,924.00
- Department Of Health And Human Services (Hhs)
- HHSO100201600002C
- Advanced Development Of Ceftobiprole
- 6 Aug 2021
- Advanced Development Of Ceftobiprole
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $108,736,742.00
- Department Of Health And Human Services (Hhs)
- HHSO100201600002C
- Advanced Development Of Ceftobiprole
- 30 Sep 2019
- Advanced Development Of Ceftobiprole
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $102,908,924.00
- Department Of Health And Human Services (Hhs)
- HHSO100201600002C
- Advanced Development Of Ceftobiprole
- 28 Apr 2022
- Advanced Development Of Ceftobiprole
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $108,736,742.00
- Department Of Health And Human Services (Hhs)
- HHSO100201600002C
- Advanced Development Of Ceftobiprole
- 28 Sep 2022
- Advanced Development Of Ceftobiprole
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $111,893,742.00
- Department Of Health And Human Services (Hhs)
- HHSO100201300010C
- Igf::Ot::Igf For Other Functions This Contract Is For The Clinical Development Of Bal30072, A Novel Monosulfactam For The Treatment Of Infections Caused By Multi-Drug Resistant Gram-Negative Bacterial Pathogens.
- 19 Sep 2018
- Igf::Ot::Igf For Other Functions This Contract Is For The Clinical Development Of Bal30072, A Novel Monosulfactam For The Treatment Of Infections Caused By Multi-Drug Resistant Gram-Negative Bacterial Pathogens.
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $13,096,576.00
- Department Of Health And Human Services (Hhs)
- HHSO100201600002C
- Advanced Development Of Ceftobiprole
- 11 Dec 2023
- Advanced Development Of Ceftobiprole
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $111,893,742.00
- Department Of Health And Human Services (Hhs)
- HHSO100201600002C
- Advanced Development Of Ceftobiprole
- 16 Sep 2020
- Advanced Development Of Ceftobiprole
- Office Of Acq&Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $104,408,924.00
- Department Of Health And Human Services (Hhs)
- HHSO100201600002C
- Advanced Development Of Ceftobiprole
- 25 May 2023
- Advanced Development Of Ceftobiprole
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $111,893,742.00
- Department Of Health And Human Services (Hhs)
- HHSO100201600002C
- Igf::Ot::Igf Advanced Development Of Ceftobiprole
- 11 Sep 2018
- Igf::Ot::Igf Advanced Development Of Ceftobiprole
- Office Of Acq Mgmt Policy
- Department Of Health And Human Services (Hhs)
- $94,908,924.00
- Department Of Health And Human Services (Hhs)